Zolmitriptan-induced growth hormone release in humans:: mediation by 5-HT1D receptors?

被引:18
作者
Whale, R [1 ]
Bhagwagar, Z [1 ]
Cowen, PJ [1 ]
机构
[1] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England
基金
英国惠康基金;
关键词
zolmitriptan; triptan; growth hormone; prolactin; ketanserin; 5-HT1D receptor;
D O I
10.1007/s002130051052
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Effective neuroendocrine probes of 5-HT1B and 5-HT1D receptor function may facilitate investigation of the role of these receptor subtypes in the pathophysiology of depression and the mode of action of antidepressant medication. Objective: To investigate the neuroendocrine profile of the 5-HT1B/1D receptor agonist, zolmitriptan, in healthy volunteers. Methods: Twelve subjects entered a double-blind, placebo-controlled, cross-over design study of zolmitriptan (5 mg orally). Blood samples were taken at 15-min intervals for assay of prolactin and growth hormone. A further six healthy men were recruited to an equivalent study to examine the effect of ketanserin (a 5-HT receptor antagonist with some preference for 5-HT1D over 5-HT1B receptors) on the growth hormone response to zolmitriptan. Results: Zolmitriptan significantly increased plasma growth hormone but had no effect on plasma prolactin or oral temperature. The increase in growth hormone produced by zolmitriptan was significantly attenuated by ketanserin. Conclusions: We suggest that the ability of triptans such as zolmitriptan, sumatriptan and rizatriptan to increase plasma growth hormone is mediated by their common agonist activity at postsynaptic 5-HT1D receptors.
引用
收藏
页码:223 / 226
页数:4
相关论文
共 22 条
[11]   Pre-clinical pharmacology of zolmitriptan (Zomig(TM); formerly 311C90), a centrally and peripherally acting 5HT(1B)/(1D) agonist for migraine [J].
Martin, GR .
CEPHALALGIA, 1997, 17 :4-14
[12]   Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: Selectively targeting additional sites of action [J].
Martin, GR .
EUROPEAN NEUROLOGY, 1996, 36 :13-18
[13]   SEROTONIN AUTORECEPTOR SUBSENSITIVITY AND ANTIDEPRESSANT ACTIVITY [J].
MORET, C ;
BRILEY, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 180 (2-3) :351-356
[14]  
Pauwels PJ, 1996, N-S ARCH PHARMACOL, V353, P144
[15]   5-HTID RECEPTORS REGULATE 5-HT RELEASE IN THE RAT RAPHE NUCLEI - IN-VIVO VOLTAMMETRY AND IN-VITRO SUPERFUSION STUDIES [J].
PINEYRO, G ;
DEMONTIGNY, C ;
BLIER, P .
NEUROPSYCHOPHARMACOLOGY, 1995, 13 (03) :249-260
[16]   THE EFFECT OF KETANSERIN, A SPECIFIC SEROTONIN ANTAGONIST ON THE PRL, GH, ACTH AND CORTISOL RESPONSES TO HYPOGLYCEMIA IN NORMAL SUBJECTS [J].
PRESCOTT, RWG ;
KENDALLTAYLOR, P ;
WEIGHTMAN, DR ;
WATSON, MJ ;
RATCLIFFE, WA .
CLINICAL ENDOCRINOLOGY, 1984, 20 (02) :137-142
[17]   Differential effects of 5-HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions [J].
Roberts, C ;
Belenguer, A ;
Middlemiss, DN ;
Routledge, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 346 (2-3) :175-180
[18]   Initial human experience with MK-462 (rizatriptan): A novel 5-HT1D agonist [J].
Sciberras, DG ;
Polvino, WJ ;
Gertz, BJ ;
Cheng, HY ;
Stepanavage, M ;
Wittreich, J ;
Olah, T ;
Edwards, M ;
Mant, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (01) :49-54
[19]   INVIVO EFFECTS OF SUMATRIPTAN (GR-43175) ON EXTRACELLULAR LEVELS OF 5-HT IN THE GUINEA-PIG [J].
SLEIGHT, AJ ;
CERVENKA, A ;
PEROUTKA, SJ .
NEUROPHARMACOLOGY, 1990, 29 (06) :511-513
[20]   Sumatriptan lowers plasma prolactin in healthy female volunteers [J].
Whale, R ;
Cowen, PJ .
PSYCHOPHARMACOLOGY, 1998, 137 (02) :203-204